Tools
Stock profile

USANA HEALTH SCIENCES INC (USNA)

USNA · Latest close $13.22 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$13.22
As of Nov 18, 2026
Tracked funds holding
1 of 149
2026 Q2 13F filings
Opened / added
0 / 1
vs previous quarter
Trimmed / exited
0
vs previous quarter

USANA HEALTH SCIENCES INC (USNA) is held by 1 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund adding versus the previous quarter. Latest close $13.22 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: none in the last 90 days · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Fundamentals
Revenue · FY2026
Red flags
none flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Government relations · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Pzena Investment Management — 1 tracked fund hold USNA. See all holders.

Insider and Congress activity

No insider open-market activity or Congress trades reported for this stock in the recent window. Insider trading · Politician trading.

Often held alongside

Merck & Co., Inc. (MRK) · LINDE PLC (LIN) · ELI LILLY & Co (LLY) · PROCTER & GAMBLE Co (PG) · PFIZER INC (PFE) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Pzena Investment Management0.08%1,205,587ADDED (+8.7%) Q3 filed Oct 30

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: -37.5% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

40.0211.642024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding138 of 8,857 filers
Long-only filers among them138
Change vs 2026 Q1+6 net · 135 entered · 129 exited
Shares reported, all filers11,386,513
Reported value, all filers$239.9M

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNYSE
IndustryMedicinal Chemicals & Botanical Products (SIC 2833)
Revenue · FY2026$925.3M
Net income · FY2026$10.8M
Total assets · FY2026$742.9M
Shares outstanding18,476,534
Market cap (at latest close)$244.3M

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Aug 11, 2026.

Short interest

Shares short · Oct 15, 2026779,033
Share of shares outstanding4.22%
Days to cover4.43

Shares short at recent settlements — Jul 31, 2026: 690K · Aug 14, 2026: 756K · Aug 31, 2026: 646K · Sep 15, 2026: 755K · Sep 30, 2026: 772K · Oct 15, 2026: 779K.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Aug 11, 2026.

Fails to deliver

Shares failed to deliver · Oct 14, 20260
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 20260.0%

Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Aug 11, 2026.

Insider trading · Form 4

Data unavailable — no Form 4 transactions for this ticker were parsed in the last 90 days.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Jun 16, 2026BRENT LOWELL NEIDIGOfficer5,002$97.3KJun 16, 2026SEC filing
Jun 15, 2026BRENT LOWELL NEIDIGOfficer909$18.2KJun 15, 2026SEC filing
Jun 8, 2026PAUL A JONESOfficer5,561$102.9KJun 8, 2026SEC filing
May 28, 2026PAUL A JONESOfficer6,813$129.1KMay 28, 2026SEC filing
May 27, 2026GARY DOUGLAS HEKKINGOfficer5,360$100.5KMay 27, 2026SEC filing
May 7, 2026JOSHUA FOUKASOfficer3,791$75.1KMay 7, 2026SEC filing
Mar 3, 2026PETER G BENEDICTOfficer4,553$88.3KMar 3, 2026SEC filing
Feb 20, 2026JOSHUA FOUKASOfficer4,461$95.2KFeb 20, 2026SEC filing
Dec 10, 2025PETER G BENEDICTOfficer2,673$56.0KDec 10, 2025SEC filing
Aug 28, 2025PAUL A JONESOfficer5,169$165.4KAug 28, 2025SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

Activist disclosure · Schedule 13D

FiledFormPrice change since disclosure
Mar 30, 2026SCHEDULE 13D/A-22.3% (close Mar 31, 2026 → Nov 17, 2026)

Reference close is the first trading day after the filing (Mar 31, 2026). A Schedule 13D reports beneficial ownership, not a purchase — there is no transaction price to show. Source: SEC EDGAR Schedule 13D filings.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Aug 13, 2026Renaissance Technologies LLCSC 13G/A958,5205.2%Jun 30, 2026SEC filing
Mar 30, 2026Gull Global LimitedSC 13D/A7,408,34540.1%Mar 26, 2026SEC filing
Mar 27, 2026The Vanguard GroupSC 13G/A00.0%Mar 13, 2026SEC filing
Jan 21, 2026BlackRock, Inc.SC 13G/A799,2964.4%Dec 31, 2025SEC filing
Jan 21, 2026Dimensional Fund Advisors LPSC 13G/A848,4524.6%Dec 31, 2025SEC filing
Oct 14, 2025PZENA INVESTMENT MANAGEMENT LLCSC 13G/A1,212,5886.6%Sep 30, 2025SEC filing
Oct 9, 2025Dimensional Fund Advisors LPSC 13G915,0495.0%Sep 30, 2025SEC filing
Jul 29, 2025The Vanguard GroupSC 13G/A1,011,7835.4%Jun 30, 2025SEC filing
Apr 30, 2025The Vanguard GroupSC 13G/A1,373,9087.3%Mar 31, 2025SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).

Committee jurisdiction

Industry: Medicinal Chemicals & Botanical Products (SIC 2833). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

None of the members who traded this stock in the current window sit on these committees.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Government relations

Lobbying: 42 Lobbying Disclosure Act filings named this company as client, 2017–2026; most common issues: Labor Issues/Antitrust/Workplace (29), Telecommunications (23), Consumer Issues/Safety/Products (13).

Federal contracts: no obligated amounts found for this ticker (USASpending, fiscal years 2021–2026).

Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.

Screens & lenses

Financial Screens

· Graham — Sound finances and a long run of profits

· Piotroski — Financial health improved over the past year

· Gross Profitability (Novy-Marx) — High gross profit relative to total assets

· Earnings Quality (Cash Conversion) — Profits that actually come back as cash

· Earnings Stability — Small earnings swings and almost no loss years

Key figures

· Graham — Current ratio: 2.24 · Straight profitable years: 14 · Debt ratio: 0.29 · Latest net income: $10.8M

· Piotroski — F-score: 7 · Return on assets: 1.5% · Operating cash flow: $22.3M

· Gross Profitability (Novy-Marx) — Gross profit / assets: 97.5% · Gross margin: 78.3%

· Earnings Quality (Cash Conversion) — Cash conversion (3-yr avg): 1.55 · Operating cash flow: $22.3M · Net income: $10.8M

· Earnings Stability — Earnings variation (CV): 0.44 · Loss years (of 10): 0 · Latest net income: $10.8M

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Signal record

13F signal (2021 Q3 – 2026 Q1)EventsWin rateAvg returnSPYExcess
Share count tripled (3x)10.0%-18.4%-8.2%-10.2%

Measured from SEC 13F filings: entry at the close on the first trading day after each quarter’s filing deadline, exit one quarter later on the same rule, dividend-adjusted closes. Past records do not guarantee future results — see Track Record and Methodology.

Also held by the tracked funds that hold USNA — ranked by lift, the co-holding pattern described in Methodology: Merck & Co., Inc. (MRK) · LINDE PLC (LIN) · ELI LILLY & Co (LLY) · PROCTER & GAMBLE Co (PG) · PFIZER INC (PFE) · AbbVie Inc. (ABBV) · BRISTOL MYERS SQUIBB CO (BMY) · COLGATE PALMOLIVE CO (CL).

8 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.

Recent 8-K filings

FiledItemsSource
Nov 3, 20262.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and ExhibitsSEC filing
Oct 5, 20261.01 Entry into a Material Definitive Agreement · 2.03 Creation of a Direct Financial Obligation · 9.01 Financial Statements and ExhibitsSEC filing
Aug 4, 20262.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and ExhibitsSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

Merck & Co., Inc. (MRK) · Track Record: how the signals scored · Practice timing on USNA

One email a week: the week’s new filings and research. Subscribe free

← USFD  ·  UTG →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.